
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion is developing novel vaccines using their proprietary AI platform, AI-Immunology, which decodes the human immune system to target cancer and infectious diseases. The company's strong focus on personalized treatment options, with 15 shared ERV antigens across 95% of AML patients in their Phase 1 trial, showcases their potential in the market. With sufficient funding into 2H27, the company plans to pivot into autoimmune disease therapies, with their AI-Immunology model set to select 2-3 lead indications in 1H26. This strategic move could positively impact their licensing strategy and further drive their growth in the future.
Bears say
Evaxion is a clinical-stage TechBio company that is facing several potential risks, including potential technology and clinical issues, as well as competition in the market. Despite presenting strong data, the company is still in the early stages of developing its pipeline, and there are currently no approved products. Its financials show a strong balance sheet, but with multiple clinical candidates in different disease areas, it may be difficult to fully capitalize on the potential value of each candidate. Overall, the company's outlook is dependent on its ability to successfully progress its pipeline and secure partnerships and collaborations to drive future revenue and growth.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares